“Swiss research institute established to focus on immune engineering and advancing global child and adolescent health.”
First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Psychedelic Invest
The multi-centre, quadruply-masked Phase IIb study aims to assess the efficacy and safety of different doses of BPL-003 in patients with Treatment Resistant Depression (TRD).
October 25, 2023